16 and older, any sex, with COPD or Interstitial Lung Disease. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Change in FEV1 From Baseline Among COPD PatientsPrimary· Measurements pre-treatment and then at 6 months post- treatment
Change from baseline (among COPD patients only) as measured by pulmonary function testing/spirometry at baseline and again at 6 months post- treatment
Group
Value
95% CI
Cell Therapy Treated
12.8
0 – 100
Number of Participants Reporting an Improvement in 3 Month-Post Treatment QOL Scores, All DiagnosesPrimary· Measurements pre-treatment and then at 3 months post-treatment for all diagnoses
Number of patients in the total sample who reported an improved perceived quality of life 3 months post-treatment as measured by the Clinical COPD Questionnaire (CCQ).
Group
Value
95% CI
Cell Therapy Treated
121
Number of Participants Reporting an Improvement in 6 Month-Post Treatment QOL Scores, All DiagnosesPrimary· Measurements pre-treatment and then at 6 months post-treatment among all diagnoses
Number of patients in the total sample who reported an improved perceived quality of life 6 months post-treatment as measured by the Clinical COPD Questionnaire (CCQ).
Group
Value
95% CI
Cell Therapy Treated
90
Number of Participants With COPD Reporting an Improvement in 3 Month-Post Treatment QOL ScoresSecondary· Measurements for COPD pre-treatment and then at 3 months post-treatment
Number of patients with a diagnosis of COPD who reported an improved perceived quality of life 3 months post-treatment as measured by the Clinical COPD Questionnaire (CCQ).
Group
Value
95% CI
Cell Therapy Treated
102
Number of Participants With COPD Reporting an Improvement in 6 Month-Post Treatment QOL ScoresSecondary· Measurements for COPD pre-treatment and then at 6 months post-treatment
Number of patients with a diagnosis of COPD who reported an improved perceived quality of life 6 months post-treatment as measured by the Clinical COPD Questionnaire (CCQ).
Group
Value
95% CI
Cell Therapy Treated
79
Number of Participants With Interstitial Lung Disease Reporting an Improvement in 3 Month-Post Treatment QOL ScoresSecondary· Measurements for ILD pre-treatment and then at 3 months post-treatment
Number of patients with a diagnosis of Interstitial Lung Disease who reported an improved perceived quality of life 3 months post-treatment as measured by the Clinical COPD Questionnaire (CCQ).
Group
Value
95% CI
Cell Therapy Treated
20
Number of Participants With Interstitial Lung Disease Reporting an Improvement in 6 Month-Post Treatment QOL ScoresSecondary· Measurements for ILD pre-treatment and then at 6 months post-treatment
Number of patients with a diagnosis of Interstitial Lung Disease who reported an improved perceived quality of life 6 months post-treatment as measured by the Clinical COPD Questionnaire (CCQ).
Group
Value
95% CI
Cell Therapy Treated
13
Adverse events — posted to ClinicalTrials.gov
Time frame: Adverse events monitoring and reporting was done over the entire length of the study, approximately 11 months from March 2016 through December 2016..
Reporting threshold: 0.2%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
The purpose of the Lung Institute is to collect and isolate a patient's own cells and platelet rich plasma (PRP) and deliver the product back to the patient the same day. Lung Institute's treatment is limited to self-funded patients with chronic lung disease- chronic obstructive pulmonary disease (COPD) and restrictive lung diseases such as pulmonary fibrosis (PF) and interstitial lung disease (ILD). The patient's cells and platelet rich plasma are harvested through venous or bone marrow collection techniques.
The hypothesized outcomes of therapy are safety and minimization of adverse events, a perceived improvement in the patient's lung condition (to be determined by their perceived quality of life), an improvement in the FEV1 among COPD patients, the ability to reduce supplemental oxygen use, the ability to function well without the use of rescue inhalers, reduction of secondary pulmonary infections, reduction in emergency room visits and exacerbations related to their disease.
Publications & conference data
5 peer-reviewed publications reference this trial (live from Europe PMC):
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Lung Institute
Last refreshed: 15 October 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03044431.